PainReform Ltd. (PRFX)
| Previous close | 0.8300 |
| Open | 0.8110 |
| Bid | 0.7687 x 100 |
| Ask | 0.8904 x 100 |
| Day's range | 0.8100 - 0.8499 |
| 52-week range | 0.4170 - 26.4100 |
| Volume | |
| Avg. volume | 140,192 |
| Market cap | 2.004M |
| Beta (5Y monthly) | 0.53 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.1400 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.00 |
GlobeNewswirePainReform Announces Closing of $4 Million Public Offering
TEL AVIV, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the closing of its previously announced public offering of an aggregate of 5,000,000 of the Company’s ordinary shares (or ordinary share equivalents) and warrants to purchase up to 5,000,000 ordinary shares at a combined public offering price of $0.80 per sha
- GlobeNewswire
PainReform Announces Pricing of $4 Million Public Offering
TEL AVIV, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the pricing of a public offering of an aggregate of 5,000,000 of the Company’s ordinary shares (or ordinary share equivalents) and warrants to purchase up to 5,000,000 ordinary shares at a combined public offering price of $0.80 per share (or per ordinary sha
BenzingaEXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions
PainReform Ltd (NASDAQ:PRFX) announced results from new studies demonstrating the superior in-vitro release (IVR) rates of PRF-110 compared to topical post-surgical pain management products available in the market. These findings underscore PainReform’s commitment to advancing non-opiate pain relief options and mark a significant milestone in developing long-lasting pain management solutions. Leveraging the latest IVR technology, which automates the testing of drug release from formulations over
